In September 2005, New Scientist reported that researchers at the Canberra Institute of Technology had identified a new type of Cannabis based on analysis of mitochondrial and chloroplast DNA. The New Scientist story, which was picked up by many news agencies and web sites, indicated that the research was to be published in the journal Forensic Science International.
The confusion compounds when one realizes that in today’s popular lexicon, the terms indica, sativa, and hybrid tend to indicate a set of effects, rather than the taxonomy of a particular strain. But that’s just as well. Most marijuana strains today, especially those under commercial cultivation, are genetic hybrids. Only a handful of pure, or “landrace” cannabis strains are in circulation.
But he wasn’t finished. In February of 1980, Dr. Mechoulam teamed up with South American researchers to publish a study regarding cannabis and epilepsy. This study is seen as one of the earliest double-blind studies of CBD on clinical subjects. The study Dr. Mechoulam and his team conducted included 16 people, many of whom were children, who all suffered from severe epilepsy. The results were startling: Every subject who received CBD experienced improvement in their condition with little to no side effects. This anticonvulsant study has since proven to be an integral milestone in the world of clinical marijuana research, but largely went unnoticed at the time.
CBD treats are safe for dogs to consume because CBD compound infused in the product is not toxic and not psychoactive. Cannabidiol compound also acts pain reliever for your dogs. The CBD compound in dog treats stimulates the endocannabinoid system which is responsible for the regulation and balance. Cannabidiol boosts the endocannabinoid system to function correctly, therefore, making the dog healthy. Endocannabinoid system is associated with mood, sleeping habits, energy balance and immunity of your pet.
In a study whose findings have not yet been published, he and a colleague, Daniel Friedman, found that patients receiving CBD in addition to their usual medicines had 39 percent fewer convulsive seizures than patients who remained on their normal drug regimen. Given that the study included only the most treatment-resistant patients, this is an “excellent response,” Devinsky says.
There is reasonable evidence from prospective epidemiological studies which suggests that cannabis use can precipitate schizophrenia in persons who are vulnerable because of a personal or family history of schizophrenia. There is also evidence that a genetic vulnerability to psychosis increases the risk that cannabis users will develop psychosis (McGuire et al., 1995; Arseneault et al., 2002; Verdoux et al., 2002). A casual relationship also has biological plausibility in that the cannabinoid and dopaminergic neurotransmitter systems interact in animals. D'Souza and colleagues (1999) have shown in a provocation study that THC produces a dose-dependent increase in psychotic symptoms under double-blind placebo conditions; and Caspi and colleagues (2005) have shown an interaction between specific alleles of the COMT allele and psychotogenic effects of cannabis. If these results can be replicated and extended, they will increase the likelihood that cannabis can be a contributory cause of psychosis in vulnerable individuals.